<< Back To Search

Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT03761108
Age 18 +
Sex Both
Phase Phase 1, Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key details about the study:
  • The treatment involves a combination of existing therapies that have shown promise in previous studies.
  • It aims to enhance the effectiveness of the treatment by targeting multiple pathways involved in the disease.
  • Patients will receive the treatment in a controlled environment, allowing researchers to closely monitor their progress and side effects.
  • The study includes a diverse group of participants to ensure the findings are applicable to a wide range of patients.
  • Researchers are particularly interested in how this combination therapy can improve overall survival rates and quality of life for patients.
  • Regular assessments will be conducted to evaluate the treatment's effectiveness and any potential side effects.
Overall, this study is unique because it combines multiple treatment strategies in a way that has not been extensively tested before. By focusing on a comprehensive approach, the researchers hope to provide new options for patients and improve their chances of a better outcome.
Third Opinion AI Generated Synopsis

Trial Summary
The main purpose of this study is to learn about the safety of REGN5458 and to find out what is the best dose of REGN5458 to give to patients with multiple myeloma. An additional purpose is to look for any signs that REGN5458 can treat cancer. The study is looking at several other research questions, including: * Side effects that may be experienced by people receiving REGN5458 * How REGN5458 works in the body * How much REGN5458 is present in the blood * How REGN5458 may work to treat cancer
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: